Abstract
Variants in transcription factor 7-like 2 (266096218TCF7L2266096218USuser266096218Gene names have been italicized per house style. Please check and confirm whether there are other instances that need to be italicized or instances where italics have been inappropriately applied.) gene have been found strongly associated with an increased risk of type 2 diabetes, as well as with an impairment of glucagon-like peptide-1 (GLP-1) signalling chain. In rats, stimulation of central GLP-1 receptors increases heart rate and activates autonomic regulatory neurons. We aimed to evaluate the potential role of TCF7L2 gene polymorphisms on sympathovagal response in relation to changes in plasma insulin and/or GLP-1 concentration after glucose ingestion. Genotyping was performed for rs12255372 and rs7903146 TCF7L2 gene variants in 250 non-related healthy volunteers (mean age 27±3 years). Consistent with previous reports, both single-nucleotide polymorphisms were in strong linkage disequilibrium (D′=0.87, r2=0.76). A subset of 167 patients underwent an oral glucose tolerance test while a continuous recording of heart rate variability was performed. At baseline, no differences in fasting plasma insulin, in GLP-1 levels and in LF/HF (low frequency/high frequency) ratio between the three genotypes were found. Along with glucose ingestion TT subjects had lower INSAUC (insulin area under curve), as well as higher LF/HFAUC (LF/HF area under curve) values. No difference in GLP-1AUC (GLP-1 area under curve) between TCF7L2 gene variants was found. A multivariate analysis including multiple covariates showed that only INSAUC, GLP-1AUC and TCF7L2 gene variants were independently associated with LF/HFAUC. In conclusion, TT genotype of rs12255372 and rs7903146 TCF7L2 gene variants is associated with lower insulin secretion and higher cardiosympathetic activity. Moreover, such effect is independent of GLP-1 and insulin plasma concentrations suggesting a potential role of such gene variants in increasing cardiovascular risk through enhanced sympathetic nervous system activity.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Jin T, Liu L : The Wnt signalling pathway effector TCF7L2 and type II diabetes mellitus. Mol Endocrinol 2008; 22: 2383–2392.
Yu M, Moreno C, Hoagland KM et al: Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens 2003; 21: 1125–1135.
Grant SF, Thorleifsson G, Reynisdottir I et al: Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006; 38: 320–323.
Groves CJ, Zeggini E, Minton J et al: Association analysis of 6736 U.K. subjects provides replication and confirms TCF7L2 as a type 2 diabetes susceptibility gene with a substantial effect on individual risk. Diabetes 2006; 55: 2640–2644.
Florez JC, Jablonski KA, Bayley N et al: TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 2006; 355: 241–250.
Damcott CM, Pollin TI, Reinhart LJ et al: Polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene are associated with type 2 diabetes in the Amish: replication and evidence for a role in both insulin secretion and insulin resistance. Diabetes 2006; 55: 2654–2659.
Saxena R, Gianniny L, Burtt NP et al: Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. Diabetes 2006; 55: 2890–2895.
Zhang C, Qi L, Hunter DJ et al: Variant of transcription factor 7-like 2 (TCF7L2) gene and the risk of type 2 diabetes in large cohorts of U.S. women and men. Diabetes 2006; 55: 2645–2648.
Cauchi S, Meyre D, Dina C et al: Transcription factor TCF7L2 genetic study in the French population: expression in human beta-cells and adipose tissue and strong association with type 2 diabetes. Diabetes 2006; 55: 2903–2908.
Scott LJ, Bonnycastle LL, Willer CJ et al: Association of transcription factor 7-like 2 (TCF7L2) variants with type 2 diabetes in a Finnish sample. Diabetes 2006; 55: 2649–2653.
Schafer SA, Tscritter O, Machicao F et al: Impaired glucagons-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia 2007; 50: 2443–2450.
Nystrom T, Gutniak MK, Zhang Q et al: Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004; 287: 1209–1215.
Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M : Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008; 117: 2340–2350.
Merchenthaler I, Lane M, Shughrue P : Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 1999; 403: 261–280.
Wei Y, Mojsov S : Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 1995; 358: 219–224.
Yamamoto H, Lee CE, Marcus JN et al: Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002; 110: 43–52.
Yamamoto H, Kishi T, Lee CE et al: Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J Neurosci 2003; 23: 2939–2946.
Bharucha AE, Charkoudian N, Andrews CN et al: Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans. Am J Physiol Regul Integr Comp Physiol 2008; 295: 874–880.
Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology Heart rate variability: Standards of measurements, physiological interpretation, and clinical use. Eur Heart J 1996; 17: 354–381.
Malliani A, Lombardi F, Pagani M, Cerutti S : Cardiovascular neural regulation explored in the frequency domain. Circulation 1991; 84: 1482–1492.
Paolisso G, Manzella D, Ferrara N et al: Glucose ingestion affects cardiac ANS in healthy subjects with different amounts of body fat. Am J Physiol 1997; 273: 471–478.
Paolisso G, Manzella D, Tagliamonte MR, Rizzo MR, Gambardella A, Varricchio M : Effects of different insulin infusion rates on heart rate variability in lean and obese subjects. Metabolism 1999; 48: 755–762.
Aberti KGMM, Zimmet PZ, for the WHO Consultation: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of WHO consultation. Diab Med 1998; 15: 539–553.
Kleiger RE, Stein PK, Bigger Jr JT : Heart rate variability: measurement and clinical utility. Ann Noninvasive Electrocardiol 2005; 10: 88–101.
Jonsen SJ, Andersen N : On power estimation in maximum entropy spectral analysis. Geophysics 1978; 43: 681–690.
Yi F, Brubaker PL, Jin T : TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta. J Biol Chem 2005; 280: 1457–1464.
Fehmann HC, Goke R, Goke B : Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr Rev 1995; 16: 390–410.
Seals DR, Bell C : Chronic sympathetic activation: consequence and cause of age-associated obesity? Diabetes 2004; 53: 276–284.
van Baak Marlen A : Meal-induced activation of sympathetic nervous system and its cardiovascular and thermogenic effects in man. Physiol Behav 2007; 94: 178–186.
Tsuji H, Venditti Jr FJ, Manders ES et al: Reduced heart rate variability and mortality risk in an elderly cohort. The Framingham Heart Study. Circulation 1994; 90: 878–883.
Mancia G, Bousquet P, Elghozi JL et al: The sympathetic nervous system and the metabolic syndrome. J Hypertens 2007; 25: 909–920.
Reaven GM, Lithell H, Landsberg L : Hypertension and associated metabolic abnormalities–the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334: 374–381.
Berne C, Fagius J, Pollare T, Hjemdahl P : The sympathetic response to euglycaemic hyperinsulinaemia. Evidence from microelectrode nerve recordings in healthy subjects. Diabetologia 1992; 35: 873–879.
Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL : Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 1991; 87: 2246–2252.
Schroeder EB, Chambless LE, Liao D et al: Diabetes, glucose, insulin, and heart rate variability: the Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care 2005; 28: 668–674.
Manzella D, Paolisso G : Cardiac autonomic activity and type II diabetes mellitus. Clinical Science 2005; 108: 93–99.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on European Journal of Human Genetics website
Rights and permissions
About this article
Cite this article
Boccardi, V., Ambrosino, I., Papa, M. et al. Potential role of TCF7L2 gene variants on cardiac sympathetic/parasympathetic activity. Eur J Hum Genet 18, 1333–1338 (2010). https://doi.org/10.1038/ejhg.2010.117
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/ejhg.2010.117
